Moderna (NASDAQ:MRNA) Shares Down 5.6% - Time to Sell?

Key Points

• Moderna's stock has decreased by 5.6%, trading at $23.97 after reaching a low of $24.79, with volume significantly down at 2.3 million shares compared to the usual average of 10.7 million.
• Analysts' ratings vary, with one Strong Buy, three Buy, sixteen Hold, and four Sell ratings, leading to a consensus target price of $42.88.
• The company reported a loss of ($2.13) EPS, but beat analysts' expectations, while revenue fell by 41.1% year-over-year to $142 million.

Moderna, Inc. (NASDAQ:MRNA - Get Free Report) traded down 5.6% during mid-day trading on Friday . The stock traded as low as $24.79 and last traded at $23.97. 2,349,227 shares traded hands during mid-day trading, a decline of 78% from the average session volume of 10,697,786 shares. The stock had previously closed at $25.39.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Leerink Partners cut their price target on shares of Moderna from $18.00 to $15.00 and set an "underperform" rating on the stock in a report on Friday, August 22nd. Bank of America cut their price target on shares of Moderna from $26.00 to $25.00 and set an "underperform" rating on the stock in a report on Tuesday, July 22nd. JPMorgan Chase & Co. set a $26.00 price target on shares of Moderna in a report on Friday, August 1st. Evercore ISI set a $32.00 price target on shares of Moderna in a report on Friday, August 1st. Finally, William Blair reaffirmed a "market perform" rating on shares of Moderna in a report on Monday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, sixteen have given a Hold rating and four have given a Sell rating to the company's stock. According to data from MarketBeat, Moderna presently has a consensus rating of "Hold" and a consensus target price of $42.88.

Moderna Stock Down 8.0%

The company's 50 day moving average price is $28.48 and its 200 day moving average price is $28.28. The firm has a market capitalization of $9.09 billion, a price-to-earnings ratio of -3.09 and a beta of 1.93.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.99) by $0.86. The company had revenue of $142.00 million during the quarter, compared to the consensus estimate of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The firm's quarterly revenue was down 41.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. As a group, analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. S Bank Fund Management Ltd acquired a new position in Moderna during the first quarter valued at $25,000. Rothschild Investment LLC lifted its position in Moderna by 94.1% during the second quarter. Rothschild Investment LLC now owns 920 shares of the company's stock valued at $25,000 after purchasing an additional 446 shares during the period. TD Private Client Wealth LLC lifted its position in Moderna by 348.8% during the second quarter. TD Private Client Wealth LLC now owns 956 shares of the company's stock valued at $26,000 after purchasing an additional 743 shares during the period. Atlantic Union Bankshares Corp acquired a new position in Moderna during the second quarter valued at $26,000. Finally, SVB Wealth LLC acquired a new position in Moderna during the first quarter valued at $28,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.